
Theodore E Warkentin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6246133/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin. New England Journal of Medicine, 1995, 332, 1330-1336.	27.0	2,664
2	Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine, 2021, 384, 2092-2101.	27.0	1,765
3	Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest, 2001, 119, 64S-94S.	0.8	1,275
4	Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood, 2000, 96, 1703-1708.	1.4	976
5	Temporal Aspects of Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2001, 344, 1286-1292.	27.0	925
6	Evaluation of pretest clinical score (4 T's) for the diagnosis of heparinâ€induced thrombocytopenia in two clinical settings. Journal of Thrombosis and Haemostasis, 2006, 4, 759-765.	3.8	916
7	A 14-year study of heparin-induced thrombocytopenia. American Journal of Medicine, 1996, 101, 502-507.	1.5	872
8	Treatment and Prevention of Heparin-Induced Thrombocytopenia. Chest, 2008, 133, 340S-380S.	0.8	783
9	Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention. Chest, 2004, 126, 311S-337S.	0.8	766
10	Heparin-induced thrombocytopenia and cardiac surgery. Annals of Thoracic Surgery, 2003, 76, 2121-2131.	1.3	638
11	Heparinâ€induced thrombocytopenia: pathogenesis and management. British Journal of Haematology, 2003, 121, 535-555.	2.5	492
12	American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances, 2018, 2, 3360-3392.	5.2	448
13	Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis. Annals of Internal Medicine, 2001, 135, 502.	3.9	429
14	The Pathogenesis of Venous Limb Gangrene Associated with Heparin-Induced Thrombocytopenia. Annals of Internal Medicine, 1997, 127, 804.	3.9	427
15	Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood, 2012, 120, 4160-4167.	1.4	393
16	Dalteparin versus Unfractionated Heparin in Critically III Patients. New England Journal of Medicine, 2011, 364, 1305-1314.	27.0	382
17	The unique characteristics of COVID-19 coagulopathy. Critical Care, 2020, 24, 360.	5.8	366
18	Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis.	3.4	352

Thrombosis and Haemostasis, 2005, 94, 132-135.

#	Article	IF	CITATIONS
19	Quantitative interpretation of optical density measurements using PF4â€dependent enzymeâ€immunoassays. Journal of Thrombosis and Haemostasis, 2008, 6, 1304-1312.	3.8	333
20	Diagnosis and management of sepsisâ€induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1989-1994.	3.8	325
21	Autoimmune heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2017, 15, 2099-2114.	3.8	319
22	An Improved Definition of Immune Heparin-Induced Thrombocytopenia in Postoperative Orthopedic Patients. Archives of Internal Medicine, 2003, 163, 2518.	3.8	287
23	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. New England Journal of Medicine, 2016, 375, 1937-1945.	27.0	278
24	Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood, 2005, 106, 3791-3796.	1.4	271
25	Heparin-Induced Thrombocytopenia Associated with Fondaparinux. New England Journal of Medicine, 2007, 356, 2653-2655.	27.0	265
26	Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?. Translational Research, 2005, 146, 341-346.	2.3	261
27	Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood, 2008, 111, 4871-4879.	1.4	260
28	Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood, 2006, 108, 2937-2941.	1.4	259
29	Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link?. Lancet, The, 1992, 340, 35-37.	13.7	254
30	Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood, 2021, 138, 2256-2268.	1.4	228
31	Heparinâ€induced thrombocytopenia: a prospective study on the incidence, plateletâ€activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. Journal of Thrombosis and Haemostasis, 2007, 5, 1666-1673.	3.8	224
32	Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood, 2012, 119, 2172-2174.	1.4	219
33	Bivalirudin. Thrombosis and Haemostasis, 2008, 99, 830-839.	3.4	211
34	Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Journal of Critical Care, 2005, 20, 348-353.	2.2	210
35	What is the potential for overdiagnosis of heparinâ€induced thrombocytopenia?. American Journal of Hematology, 2007, 82, 1037-1043.	4.1	209
36	The direct thrombin inhibitor hirudin. Thrombosis and Haemostasis, 2008, 99, 819-829.	3.4	207

#	Article	IF	CITATIONS
37	Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood, 2001, 98, 1842-1846.	1.4	198
38	Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood, 2005, 105, 139-144.	1.4	196
39	Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood, 2000, 96, 188-194.	1.4	190
40	Heparin-induced thrombocytopenia and cardiac surgery. Annals of Thoracic Surgery, 2003, 76, 638-648.	1.3	187
41	Optical Densities Reduce Odds of Heparin-induced Thrombocytopenia Over-diagnosis. American Journal of Medicine, 2012, 125, 3-4.	1.5	185
42	Heparin-induced thrombocytopenia in intensive care patients. Critical Care Medicine, 2007, 35, 1165-1176.	0.9	179
43	Heparinâ€induced thrombocytopenia and thrombosis: clinical and laboratory studies. British Journal of Haematology, 1993, 84, 322-328.	2.5	175
44	Heparinâ€induced skin lesions. British Journal of Haematology, 1996, 92, 494-497.	2.5	175
45	Heparin-induced thrombocytopenia: a historical perspective. Blood, 2008, 112, 2607-2616.	1.4	172
46	Suboptimal effect of a threeâ€factor prothrombin complex concentrate (Profilnineâ€5D) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion, 2009, 49, 1171-1177.	1.6	172
47	Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfusion Medicine Reviews, 2003, 17, 272-286.	2.0	171
48	Thrombocytopenia in Critically III Patients Receiving Thromboprophylaxis. Chest, 2013, 144, 1207-1215.	0.8	171
49	Heparin-Induced Thrombocytopenia. Circulation, 2004, 110, e454-8.	1.6	165
50	Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood, 2003, 101, 3049-3051.	1.4	164
51	Drug-Induced Immune-Mediated Thrombocytopenia — From Purpura to Thrombosis. New England Journal of Medicine, 2007, 356, 891-893.	27.0	161
52	Studies of the immune response in heparin-induced thrombocytopenia. Blood, 2009, 113, 4963-4969.	1.4	157
53	Earlyâ€onset and persisting thrombocytopenia in postâ€cardiac surgery patients is rarely due to heparinâ€induced thrombocytopenia, even when antibody tests are positive. Journal of Thrombosis and Haemostasis, 2010, 8, 30-36.	3.8	157
54	Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2386-2393.	2.4	156

#	Article	IF	CITATIONS
55	Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia. New England Journal of Medicine, 2021, 385, 720-728.	27.0	156
56	A Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia. American Journal of Medicine, 2008, 121, 632-636.	1.5	154
57	The epitope specificity of heparinâ€induced thrombocytopenia. British Journal of Haematology, 1996, 95, 161-167.	2.5	152
58	Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood, 2017, 130, 1104-1113.	1.4	152
59	Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. Journal of Thrombosis and Haemostasis, 2011, 9, 2498-2500.	3.8	150
60	Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood, 2000, 96, 1703-8.	1.4	150
61	Laboratory diagnosis of immune heparin-induced thrombocytopenia. Psychophysiology, 2003, 2, 148-57.	1.1	150
62	New Approaches to the Diagnosis of Heparin-Induced Thrombocytopenia. Chest, 2005, 127, 35S-45S.	0.8	145
63	A prospective study of proteinâ€specific assays used to investigate idiopathic thrombocytopenic purpura. British Journal of Haematology, 1999, 104, 442-447.	2.5	144
64	Testing for Heparin-Induced Thrombocytopenia Antibodies. Transfusion Medicine Reviews, 2006, 20, 259-272.	2.0	142
65	Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia. Transfusion Medicine Reviews, 2013, 27, 137-145.	2.0	141
66	Clinical presentation of heparin-induced thrombocytopenia. Seminars in Hematology, 1998, 35, 9-16; discussion 35-6.	3.4	140
67	The platelet serotoninâ€ŧelease assay. American Journal of Hematology, 2015, 90, 564-572.	4.1	138
68	Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood, 2014, 123, 3651-3654.	1.4	132
69	Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thrombosis and Haemostasis, 2005, 94, 958-964.	3.4	130
70	How I Diagnose and Manage HIT. Hematology American Society of Hematology Education Program, 2011, 2011, 143-149.	2.5	129
71	HEPARIN-INDUCED THROMBOCYTOPENIA: A Ten-Year Retrospective. Annual Review of Medicine, 1999, 50, 129-147.	12.2	128
72	Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Journal of Clinical Medicine, 2019, 8, 728.	2.4	128

#	Article	IF	CITATIONS
73	Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome. Hematology American Society of Hematology Education Program, 2003, 2003, 497-519.	2.5	127
74	Fondaparinux treatment of acute heparinâ€induced thrombocytopenia confirmed by the serotoninâ€release assay: a 30â€month, 16â€patient case series. Journal of Thrombosis and Haemostasis, 2011, 9, 2389-2396.	3.8	127
75	A diagnostic test for heparinâ€induced thrombocytopenia: detection of platelet microparticles using flow cytometry. British Journal of Haematology, 1996, 95, 724-731.	2.5	125
76	Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood, 2021, 138, 299-303.	1.4	125
77	Platelet Count Monitoring and Laboratory Testing for Heparin-Induced Thrombocytopenia. Archives of Pathology and Laboratory Medicine, 2002, 126, 1415-1423.	2.5	124
78	Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. Translational Research, 1992, 120, 371-9.	2.3	124
79	Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Practice and Research in Clinical Haematology, 2004, 17, 105-125.	1.7	123
80	Heparin-Induced Skin Lesions and Other Unusual Sequelae of the Heparin-Induced Thrombocytopenia Syndrome. Chest, 2005, 127, 1857-1861.	0.8	121
81	High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Review of Hematology, 2019, 12, 685-698.	2.2	121
82	The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. Journal of Critical Care, 2010, 25, 287-293.	2.2	117
83	Heparin-Induced Thrombocytopenia. Annual Review of Medicine, 1989, 40, 31-44.	12.2	112
84	The temporal profile of the anti-PF4/heparin immune response. Blood, 2009, 113, 4970-4976.	1.4	109
85	A systematic evaluation of laboratory testing for drugâ€induced immune thrombocytopenia. Journal of Thrombosis and Haemostasis, 2013, 11, 169-176.	3.8	109
86	Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thrombosis Research, 2003, 110, 73-82.	1.7	107
87	An Overview of the Heparin-Induced Thrombocytopenia Syndrome. Seminars in Thrombosis and Hemostasis, 2004, 30, 273-283.	2.7	106
88	Failure of Anticoagulant Thromboprophylaxis. Critical Care Medicine, 2015, 43, 401-410.	0.9	106
89	Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thrombosis Research, 2008, 122, 211-220.	1.7	105
90	Heparin-Induced thrombocytopenia: IgG-Mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-Induced thrombocytopenia. Transfusion Medicine Reviews, 1996, 10, 249-258.	2.0	104

#	Article	IF	CITATIONS
91	Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood, 2021, 138, 1269-1277.	1.4	102
92	Delayed-Onset Heparin-Induced Thrombocytopenia and Cerebral Thrombosis after a Single Administration of Unfractionated Heparin. New England Journal of Medicine, 2003, 348, 1067-1069.	27.0	101
93	Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood, 2015, 126, 597-603.	1.4	101
94	Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. Journal of Thrombosis and Haemostasis, 2009, 7, 107-110.	3.8	98
95	Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. American Journal of Hematology, 2002, 71, 50-52.	4.1	95
96	Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opinion on Drug Safety, 2009, 8, 129-144.	2.4	95
97	Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood, 2005, 106, 2921-2922.	1.4	94
98	Ischemic Limb Gangrene with Pulses. New England Journal of Medicine, 2015, 373, 642-655.	27.0	92
99	Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. American Journal of Hematology, 1999, 62, 44-48.	4.1	90
100	Activation of platelets by sera containing igg1 heparin-dependent antibodies: an explanation for the predominance of the Fcl³rlla "low responder―(his131) gene in patients with heparin-induced thrombocytopenia. Translational Research, 1997, 130, 278-284.	2.3	88
101	HIT paradigms and paradoxes. Journal of Thrombosis and Haemostasis, 2011, 9, 105-117.	3.8	88
102	Heparin-Induced Thrombocytopenia in Critically Ill Patients. Seminars in Thrombosis and Hemostasis, 2015, 41, 049-060.	2.7	87
103	Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood, 1994, 84, 3691-9.	1.4	86
104	Heparin-induced thrombocytopenia in the critical care setting: Diagnosis and management^. Critical Care Medicine, 2006, 34, 2898-2911.	0.9	84
105	Laboratory diagnosis of heparinâ€induced thrombocytopenia. International Journal of Laboratory Hematology, 2019, 41, 15-25.	1.3	84
106	Heparin-induced thrombocytopenia: towards consensus. Thrombosis and Haemostasis, 1998, 79, 1-7.	3.4	84
107	Heparin-Induced Thrombocytopenia. Hematology/Oncology Clinics of North America, 2007, 21, 589-607.	2.2	83
108	How do we approach thrombocytopenia in critically ill patients?. British Journal of Haematology, 2017, 177, 27-38.	2.5	83

7

#	Article	IF	CITATIONS
109	Proposal of the Definition for COVID-19-Associated Coagulopathy. Journal of Clinical Medicine, 2021, 10, 191.	2.4	83
110	Venous Limb Gangrene during Warfarin Treatment of Cancer-Associated Deep Venous Thrombosis. Annals of Internal Medicine, 2001, 135, 589.	3.9	82
111	Measurement of fibrinogen binding to platelets in whole blood by flow cytometry: a micromethod for the detection of platelet activation. British Journal of Haematology, 1990, 76, 387-394.	2.5	81
112	Fondaparinux: does it cause HIT? can it treat HIT?. Expert Review of Hematology, 2010, 3, 567-581.	2.2	81
113	Gastrointestinal Angiodysplasia and Aortic Stenosis. New England Journal of Medicine, 2002, 347, 858-859.	27.0	79
114	Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood, 2015, 125, 195-198.	1.4	78
115	Distinguishing between anti–platelet factor 4/heparin antibodies that can and cannot cause heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2015, 13, 1900-1907.	3.8	78
116	Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Expert Opinion on Drug Safety, 2014, 13, 25-43.	2.4	76
117	Vaccineâ€induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. Journal of Thrombosis and Haemostasis, 2022, 20, 149-156.	3.8	76
118	Think of HIT. Hematology American Society of Hematology Education Program, 2006, 2006, 408-414.	2.5	75
119	Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. Journal of Thrombosis and Haemostasis, 2008, 6, 428-435.	3.8	74
120	Heparinâ€induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. Journal of Thrombosis and Haemostasis, 2010, 8, 2025-2031.	3.8	74
121	Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood, 2014, 123, 2485-2493.	1.4	74
122	Rivaroxaban for treatment of suspected or confirmed heparinâ€induced thrombocytopenia study. Journal of Thrombosis and Haemostasis, 2016, 14, 1206-1210.	3.8	74
123	Heparin-Induced Thrombocytopenia in Patients with Ventricular Assist Devices: Are New Prevention Strategies Required?. Annals of Thoracic Surgery, 2009, 87, 1633-1640.	1.3	72
124	Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. Thrombosis Research, 2021, 204, 40-51.	1.7	72
125	Fatal heparinâ€induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of †spontaneous' HIT?. Journal of Thrombosis and Haemostasis, 2008, 6, 1598-1600.	3.8	70
126	Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE. Chest, 2011, 140, 366-373.	0.8	69

#	Article	IF	CITATIONS
127	Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thrombosis and Haemostasis, 2016, 116, 813-822.	3.4	69
128	ISTH DIC subcommittee communication on anticoagulation in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2138-2144.	3.8	69
129	Heparinâ€induced thrombocytopenia – therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4–heparin complexes. Journal of Thrombosis and Haemostasis, 2008, 6, 2160-2167.	3.8	68
130	Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thrombosis Research, 2006, 117, 507-515.	1.7	66
131	Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood, 2010, 115, 29-31.	1.4	65
132	Agents for the Treatment of Heparin-Induced Thrombocytopenia. Hematology/Oncology Clinics of North America, 2010, 24, 755-775.	2.2	65
133	Anti–protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood, 2013, 121, 2821-2827.	1.4	64
134	Improving Clinical Interpretation of the Anti-Platelet Factor 4/Heparin Enzyme-Linked Immunosorbent Assay for the Diagnosis of Heparin-Induced Thrombocytopenia Through the Use of Receiver Operating Characteristic Analysis, Stratum-Specific Likelihood Ratios, and Bayes Theorem. Chest, 2013, 144, 1269-1275.	0.8	63
135	Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. Journal of Thrombosis and Haemostasis, 2006, 4, 678-679.	3.8	62
136	Nonâ€necrotizing heparinâ€induced skin lesions and the 4T's score. Journal of Thrombosis and Haemostasis, 2010, 8, 1483-1485.	3.8	62
137	Transient global amnesia associated with acute heparin-induced thrombocytopenia. American Journal of Medicine, 1994, 97, 489-491.	1.5	61
138	The effect of blood storage duration on inâ€hospital mortality: a randomized controlled pilot feasibility trial. Transfusion, 2012, 52, 1203-1212.	1.6	61
139	Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories. Thrombosis and Haemostasis, 2007, 98, 1357-1361.	3.4	60
140	Heparin-Induced Thrombocytopenia in Medical Surgical Critical Illness. Chest, 2013, 144, 848-858.	0.8	60
141	Reversing anticoagulants both old and new. Canadian Journal of Anaesthesia, 2002, 49, S11-25.	1.6	60
142	Bivalirudin: a review. Expert Opinion on Pharmacotherapy, 2005, 6, 1349-1371.	1.8	58
143	How I treat patients with a history of heparin-induced thrombocytopenia. Blood, 2016, 128, 348-359.	1.4	56
144	Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL ® HIT-Ab (PF4-H)] for the diagnosis of immune heparin-induced thrombocytopenia. Thrombosis Research, 2017, 153, 108-117.	1.7	56

#	Article	IF	CITATIONS
145	Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thrombosis and Haemostasis, 1999, 82, 439-47.	3.4	55
146	Heparin-Induced Thrombocytopenia: Real-World Issues. Seminars in Thrombosis and Hemostasis, 2011, 37, 653-663.	2.7	53
147	Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. Platelets, 1999, 10, 319-326.	2.3	52
148	Heparin-Induced Thrombocytopenia Presenting as Bilateral Adrenal Hemorrhages. New England Journal of Medicine, 2015, 372, 492-494.	27.0	52
149	Antiâ€PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of nonâ€drug risk factors and evidence for a stoichiometryâ€based model of immunization. Journal of Thrombosis and Haemostasis, 2010, 8, 504-512.	3.8	51
150	Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. Platelets, 2017, 28, 614-620.	2.3	51
151	Heparinâ€induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery â€̃spontaneous' HIT. Journal of Thrombosis and Haemostasis, 2009, 7, 499-501.	3.8	50
152	Differential diagnoses for sepsisâ€induced disseminated intravascular coagulation: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 415-419.	3.8	50
153	Intraoperative Heparin Flushes and Subsequent Acute Heparin-induced ThrombocytopeniaÂ. Anesthesiology, 1998, 89, 1567-1569.	2.5	49
154	Newer Strategies for the Treatment of Heparin-Induced Thrombocytopenia. Pharmacotherapy, 1999, 19, 181-195.	2.6	49
155	HITlights: A career perspective on heparinâ€induced thrombocytopenia. American Journal of Hematology, 2012, 87, S92-9.	4.1	48
156	Heparin-induced thrombocytopenia. Current Opinion in Critical Care, 2015, 21, 576-585.	3.2	47
157	Aspirin for Dual Prevention of Venous and Arterial Thrombosis. New England Journal of Medicine, 2012, 367, 2039-2041.	27.0	46
158	Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thrombosis and Haemostasis, 2010, 104, 1071-1072.	3.4	44
159	Heparin-induced thrombocytopenia in the critically ill: Interpreting the 4Ts test in a randomized trial. Journal of Critical Care, 2014, 29, 470.e7-470.e15.	2.2	44
160	High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT. Blood, 2018, 132, 1345-1349.	1.4	44
161	No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. Journal of Thrombosis and Haemostasis, 2006, 4, 281-282.	3.8	43
162	Incidence and clinical relevance of anti–platelet factor 4/heparin antibodies before cardiac surgery. American Heart Journal, 2010, 160, 362-369.	2.7	43

#	Article	IF	CITATIONS
163	Serotoninâ€release assayâ€negative heparinâ€induced thrombocytopenia. American Journal of Hematology, 2020, 95, 38-47.	4.1	43
164	Posttransfusion platelet count increments after ABOâ€compatible versus ABOâ€incompatible platelet transfusions in noncancer patients: an observational study. Transfusion, 2010, 50, 1552-1560.	1.6	42
165	The Role for Optical Density in Heparin-Induced Thrombocytopenia. Chest, 2015, 148, 55-61.	0.8	42
166	Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty. Platelets, 2021, 32, 936-940.	2.3	42
167	Limitations of conventional treatment options for heparin-induced thrombocytopenia. Seminars in Hematology, 1998, 35, 17-25; discussion 35-6.	3.4	42
168	Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage. Transfusion, 2004, 44, 1361-1366.	1.6	41
169	The alloimmune thrombocytopenic syndromes. Transfusion Medicine Reviews, 1997, 11, 296-307.	2.0	40
170	The use of wellâ€characterized sera for the assessment of new diagnostic enzymeâ€immunoassays for the diagnosis of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2010, 8, 216-218.	3.8	40
171	Highâ€dose intravenous immunoglobulin to treat spontaneous heparinâ€induced thrombocytopenia syndrome. Journal of Thrombosis and Haemostasis, 2019, 17, 841-844.	3.8	40
172	Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin "flushes― Thrombosis and Haemostasis, 2007, 98, 1139-1140.	3.4	39
173	Delayedâ€onset HIT caused by lowâ€molecularâ€weight heparin manifesting during fondaparinux prophylaxis. American Journal of Hematology, 2008, 83, 876-878.	4.1	39
174	Heparin-Induced Thrombocytopenia in Critically III Patients. Critical Care Clinics, 2011, 27, 805-823.	2.6	39
175	Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome. Blood, 2015, 126, 486-493.	1.4	39
176	Performance characteristics of a rapid assay for antiâ€₽F4/heparin antibodies: the particle immunofiltration assay. Journal of Thrombosis and Haemostasis, 2007, 5, 2308-2310.	3.8	38
177	The Approach to Heparin-Induced Thrombocytopenia. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 066-074.	2.1	37
178	Intravenous Immune Globulin to Prevent Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2018, 378, 1845-1848.	27.0	37
179	Proposal of a twoâ€step process for the diagnosis of sepsisâ€induced disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1265-1268.	3.8	37
180	COVID-19 versus HIT hypercoagulability. Thrombosis Research, 2020, 196, 38-51.	1.7	37

#	Article	IF	CITATIONS
181	Investigation of human platelet alloantigens and glycoproteins using non-radioactive immunoprecipitation. Journal of Immunological Methods, 1993, 158, 77-85.	1.4	36
182	Should vitamin K be administered when HIT is diagnosed after administration of coumarin?. Journal of Thrombosis and Haemostasis, 2006, 4, 894-896.	3.8	36
183	Management of heparin-induced thrombocytopenia. Current Opinion in Hematology, 2016, 23, 462-470.	2.5	36
184	Heparin, Low Molecular Weight Heparin, and Heparin-Induced Thrombocytopenia in the ICU. Critical Care Clinics, 2005, 21, 513-529.	2.6	35
185	Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thrombosis Research, 2011, 128, 256-260.	1.7	35
186	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. Lancet Haematology,the, 2017, 4, e544-e552.	4.6	34
187	When is HIT Really HIT?. Annals of Thoracic Surgery, 2007, 83, 21-23.	1.3	32
188	Can heparinâ€induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2008, 6, 1243-1246.	3.8	32
189	Diagnostic accuracy of IgGâ€specific versus polyspecific enzymeâ€linked immunoassays in heparinâ€induced thrombocytopenia: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2017, 15, 1203-1212.	3.8	32
190	Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. Blood, 2017, 130, 1679-1682.	1.4	32
191	Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis. Expert Review of Hematology, 2008, 1, 75-85.	2.2	31
192	Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT). Seminars in Hematology, 2022, 59, 89-96.	3.4	31
193	Studies of the anti–platelet factor 4/heparin immune response: adapting the enzymeâ€linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion, 2010, 50, 32-39.	1.6	30
194	Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Critical Care Medicine, 2022, 50, e80-e86.	0.9	30
195	Transfusion premedication to prevent acute transfusion reactions: a retrospective observational study to assess current practices. Transfusion, 2010, 50, 1722-1730.	1.6	29
196	Design of the rivaroxaban for heparin-induced thrombocytopenia study. Journal of Thrombosis and Thrombolysis, 2014, 38, 485-492.	2.1	29
197	Progressive thrombocytopenia after cardiac surgery in a 67-year-old man. Cmaj, 2014, 186, 929-933.	2.0	29
198	Systematic review of fondaparinux for heparinâ€induced thrombocytopenia: When there are no randomized controlled trials. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 678-683.	2.3	29

#	Article	IF	CITATIONS
199	Heparin-induced thrombocytopenia. Cmaj, 2021, 193, E736-E736.	2.0	29
200	Clinical Picture of Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 21-66.	0.0	29
201	Who Is (Still) Getting HIT?. Chest, 2007, 131, 1620-1622.	0.8	28
202	Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy. Haematologica, 2022, 107, 1219-1221.	3.5	28
203	Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study. Journal of Thrombosis and Thrombolysis, 2015, 39, 60-67.	2.1	27
204	Venous limb gangrene and fatal hemorrhage: Adverse consequences of hit "overdiagnosis―in a patient with antiphospholipid syndrome. American Journal of Hematology, 2011, 86, 188-191.	4.1	26
205	Pitfalls in the diagnosis of heparinâ€Induced thrombocytopenia: A 6â€year experience from a reference laboratory. American Journal of Hematology, 2015, 90, 629-633.	4.1	26
206	The alloimmune thrombocytopenic syndromes. Transfusion Medicine Reviews, 1997, 11, 296-307.	2.0	26
207	Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis. American Journal of Hematology, 2004, 75, 56-62.	4.1	25
208	Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. American Journal of Hematology, 2005, 78, 188-192.	4.1	25
209	HIT: Lessons Learned. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 50-57.	0.3	25
210	The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. Thrombosis and Haemostasis, 2012, 108, 394-396.	3.4	25
211	Protamine (heparin)â€induced thrombocytopenia: a review of the serological and clinical features associated with antiâ€protamine/heparin antibodies. Journal of Thrombosis and Haemostasis, 2016, 14, 1685-1695.	3.8	25
212	Platelet-activating anti-PF4 disorders: An overview. Seminars in Hematology, 2022, 59, 59-71.	3.4	25
213	An algorithm for resolving â€~indeterminate' test results in the platelet serotonin release assay for investigation of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2008, 6, 1595-1597.	3.8	24
214	PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan. Journal of Critical Care, 2011, 26, 223.e1-223.e9.	2.2	24
215	Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivation. Transfusion, 2012, 52, 529-536.	1.6	24
216	A practical approach to evaluating postoperative thrombocytopenia. Blood Advances, 2020, 4, 776-783.	5.2	24

#	Article	IF	CITATIONS
217	Current agents for the treatment of patients with heparin-induced thrombocytopenia. Current Opinion in Pulmonary Medicine, 2002, 8, 405-412.	2.6	23
218	An international external quality assessment for laboratory diagnosis of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 525-531.	3.8	23
219	Combination of two complementary automated rapid assays for diagnosis of heparinâ€induced thrombocytopenia (HIT). Journal of Thrombosis and Haemostasis, 2020, 18, 1435-1446.	3.8	23
220	So, Does Low-Molecular-Weight Heparin Cause Less Heparin-Induced Thrombocytopenia Than Unfractionated Heparin or Not?. Chest, 2007, 132, 1108-1110.	0.8	22
221	HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux- induced HIT. Thrombosis and Haemostasis, 2014, 112, 1319-1322.	3.4	22
222	Difficulties in establishing the diagnosis of immune thrombocytopenia: An agreement study. American Journal of Hematology, 2016, 91, E327-9.	4.1	22
223	Autoimmune heparinâ€induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. Transfusion, 2019, 59, 1924-1933.	1.6	22
224	Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. Thrombosis and Haemostasis, 2021, 121, 1677-1680.	3.4	22
225	Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood, 2000, 96, 1703-1708.	1.4	22
226	Contaminated Heparin. New England Journal of Medicine, 2008, 359, 1291-1293.	27.0	21
227	Immunoassays are not created equal. Journal of Thrombosis and Haemostasis, 2009, 7, 1256-1259.	3.8	21
228	Acute Hepatic Necrosis and Ischemic Limb Necrosis. New England Journal of Medicine, 2012, 367, 879-881.	27.0	21
229	Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is â€~shock liver' the unrecognized provocateur of ischemic limb necrosis?. Journal of Thrombosis and Haemostasis, 2016, 14, 231-235.	3.8	21
230	Formation of anti–platelet factor 4/heparin antibodies after cardiac surgery: Influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 1456-1463.	0.8	20
231	Frequency of Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 67-116.	0.0	20
232	Microvascular Thrombosis and Ischaemic Limb Losses in Critically Ill Patients. Hamostaseologie, 2019, 39, 006-019.	1.9	19
233	Current Concepts in the Treatment of Immune Thrombocytopenia. Drugs, 1990, 40, 531-542.	10.9	18
234	Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura. British Journal of Haematology, 1996, 93, 421-426.	2.5	18

#	Article	IF	CITATIONS
235	The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis. British Journal of Haematology, 1995, 91, 742-746.	2.5	17
236	Clinical sample investigation (CSI) hematology: pinpointing the precise onset of heparin-induced thrombocytopenia (HIT). Journal of Thrombosis and Haemostasis, 2007, 5, 636-637.	3.8	17
237	Heparin-Induced Thrombocytopenia in the ICU. Chest, 2012, 142, 815-816.	0.8	17
238	Ischemic limb necrosis in septic shock: What is the role of highâ€dose vasopressor therapy?. Journal of Thrombosis and Haemostasis, 2019, 17, 1973-1978.	3.8	17
239	Spontaneous Heparin-Induced Thrombocytopenia Presenting as Cerebral Venous Sinus Thrombosis. Neurology: Clinical Practice, 2021, 11, e929-e931.	1.6	17
240	Heparin-induced thrombocytopenia and its treatment. Journal of Thrombosis and Thrombolysis, 2000, 9, 29-35.	2.1	16
241	Think of HIT When Thrombosis Follows Heparin. Chest, 2006, 130, 631-632.	0.8	16
242	Case report: Management of immediate post-car-diopulmonary bypass massive intra-cardiac thrombosis. Canadian Journal of Anaesthesia, 2007, 54, 461-466.	1.6	16
243	Platelet-Activating Antibodies Are Detectable at the Earliest Onset of Heparin-Induced Thrombocytopenia, With Implications for the Operating Characteristics of the Serotonin-Release Assay. Chest, 2018, 153, 1396-1404.	0.8	16
244	Heparinâ€induced thrombocytopeniaâ€associated thrombosis: from arterial to venous to venous limb gangrene. Journal of Thrombosis and Haemostasis, 2018, 16, 2128-2132.	3.8	16
245	Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban. Platelets, 2020, 31, 124-127.	2.3	16
246	Intraoperative anticoagulation and limb amputations in patients with immune heparin-induced thrombocytopenia who require vascular surgery. Journal of Thrombosis and Haemostasis, 2012, 10, 148-150.	3.8	15
247	Non–injectionâ€site necrotic skin lesions complicating postoperative heparin thromboprophylaxis. American Journal of Hematology, 2015, 90, 747-750.	4.1	15
248	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. Transfusion Medicine Reviews, 2016, 30, 25-29.	2.0	15
249	Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2017, 15, 1640-1645.	3.8	15
250	Heparin-Induced Thrombocytopenia and Vascular Surgery. Acta Chirurgica Belgica, 2004, 104, 257-265.	0.4	14
251	Transient Global Amnesia as the Presenting Feature of Heparin-Induced Thrombocytopenia. Journal of Cardiac Surgery, 2010, 25, 300-302.	0.7	14
252	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. Journal of Thrombosis and Thrombolysis, 2011, 32, 378-385.	2.1	14

#	Article	IF	CITATIONS
253	Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. Thrombosis and Haemostasis, 2012, 107, 8-14.	3.4	14
254	FcγRIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2013, 11, 1146-1153.	3.8	14
255	Antiâ€PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2013, 11, 253-260.	3.8	14
256	Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. Blood, 2019, 133, 978-989.	1.4	14
257	Highâ€dose IVIG plus cangrelor platelet "anesthesia―during urgent heparin PB in a patient with recent SRAâ€negative HITâ€thrombosis with persisting plateletâ€activating antibodies. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1060-1064.	2.3	14
258	Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies – distinguishing "signal" from "noise". Thrombosis and Haemostasis, 2008, 100, 523-524.	3.4	14
259	Prospective multicentre cohort study of heparinâ€induced thrombocytopenia in acute ischaemic stroke patients. British Journal of Haematology, 2011, 154, 378-386.	2.5	13
260	Progressive, Fatal Thrombosis Associated With Heparin-Induced Thrombocytopenia After Cardiac Surgery Despite "Therapeutic―Anticoagulation With Argatroban: Potential Role for PTT and ACT Confounding. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 1319-1321.	1.3	13
261	Platelet count recovery and seroreversion in immune HIT despite continuation of heparin: further observations and literature review. Thrombosis and Haemostasis, 2017, 117, 1868-1874.	3.4	12
262	Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature. Experimental Hematology and Oncology, 2017, 6, 21.	5.0	12
263	Timeline of heparinâ€induced thrombocytopenia seroconversion in serial plasma samples tested using an automated latex immunoturbidimetric assay. International Journal of Laboratory Hematology, 2019, 41, 493-502.	1.3	12
264	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. Expert Review of Respiratory Medicine, 2021, 15, 1003-1011.	2.5	12
265	Symmetrical peripheral gangrene in critical illness. Transfusion and Apheresis Science, 2021, 60, 103094.	1.0	12
266	Adverse Prognostic Significance of Thrombocytopenia in Acute Coronary Syndrome. Circulation, 2009, 119, 2420-2422.	1.6	11
267	Chills and limb pain following administration of lowâ€molecularâ€weight heparin for treatment of acute venous thromboembolism. American Journal of Hematology, 2011, 86, 603-606.	4.1	11
268	HIT: treatment easier, prevention harder. Blood, 2012, 119, 1099-1100.	1.4	11
269	The transfusionâ€related acute lung injury controversy: lessons from heparinâ€induced thrombocytopenia. Transfusion, 2015, 55, 1128-1134.	1.6	11
270	Ischemic Limb Gangrene with Pulses. New England Journal of Medicine, 2015, 373, 2385-2388.	27.0	11

#	Article	IF	CITATIONS
271	Fondaparinux for Treatment of Heparin-Induced Thrombocytopenia. Journal of the American College of Cardiology, 2017, 70, 2649-2651.	2.8	11
272	The association between platelet transfusions and mortality in patients with critical illness. Transfusion, 2019, 59, 1962-1970.	1.6	11
273	Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses. Blood Advances, 2020, 4, 5184-5193.	5.2	11
274	Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies. Hamostaseologie, 2020, 40, 472-484.	1.9	11
275	Serotoninâ€release assayâ€positive but platelet factor 4â€dependent enzymeâ€immunoassay negative: HIT or not HIT ?. American Journal of Hematology, 2021, 96, 320-329.	4.1	11
276	Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2. Thrombosis and Haemostasis, 2022, 122, 304-307.	3.4	11
277	Heparin-induced thrombocytopenia. Psychophysiology, 2002, 1, 63-72.	1.1	11
278	Laboratory testing for VITT antibodies. Seminars in Hematology, 2022, 59, 80-88.	3.4	11
279	Spinal-cord concussion in frogs a study of reflex changes. World Neurosurgery, 1983, 20, 456-460.	1.3	10
280	Acute pancreatitis preceding thrombotic thrombocytopenic Purpura. Haematologica, 2007, 92, e94-e95.	3.5	10
281	Heyde's syndrome: From controversy to mainstream. Thrombosis and Haemostasis, 2010, 103, 251-253.	3.4	10
282	Scoring systems for heparin-induced thrombocytopenia (HIT): Whither now?. Thrombosis and Haemostasis, 2015, 113, 437-438.	3.4	10
283	Demand on-demand testing for the diagnosis of heparin-induced thrombocytopenia. Thrombosis Research, 2016, 140, 163-164.	1.7	10
284	Acute haemolysis, DIC and renal failure after transfusion of uncrossâ€matched blood during trauma resuscitation: illustrative case and literature review. Transfusion Medicine, 2018, 28, 319-325.	1.1	10
285	A comparative study of platelet factor 4â€enhanced platelet activation assays for the diagnosis of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2021, 19, 1096-1102.	3.8	10
286	Analysis of a nonsusceptible fraction with current status data. Statistics in Medicine, 2008, 27, 2715-2730.	1.6	9
287	HIT: more than just heparin. Blood, 2010, 115, 1664-1665.	1.4	9
288	IV Immunoglobulin forÂAutoimmune Heparin-Induced Thrombocytopenia. Chest, 2017, 152, 453-455.	0.8	9

17

#	Article	IF	CITATIONS
289	Neutrophil and Monocyte Counts in Heparin-Induced Thrombocytopenia. Thrombosis and Haemostasis, 2019, 119, 941-951.	3.4	9
290	Spontaneous heparin-induced thrombocytopenia syndrome presenting as bilateral adrenal infarction after knee arthroplasty. BMJ Case Reports, 2019, 12, e232769.	0.5	9
291	<i>ABO</i> O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. Blood, 2022, 140, 274-284.	1.4	9
292	A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins. Journal of Thrombosis and Haemostasis, 2012, 10, 1446-1449.	3.8	8
293	Immature Platelet Count. Journal of the American College of Cardiology, 2014, 64, 2130-2132.	2.8	8
294	Rivaroxaban for treatment of HIT: A riveting first experience. Thrombosis Research, 2015, 135, 1-2.	1.7	8
295	Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2018, 16, 1402-1412.	3.8	8
296	Reversing Anticoagulant Therapy. Current Drug Discovery Technologies, 2012, 9, 143-149.	1.2	8
297	Vaccineâ€induced immune thrombotic thrombocytopenia (VITT) ―update on diagnosis and management considering different resources: Response to Comment from Yamada et al. Journal of Thrombosis and Haemostasis, 2022, 20, 542-543.	3.8	8
298	PF4-dependent immunoassays and inferential detection of HIT antibodies. Journal of Thrombosis and Haemostasis, 2007, 5, 232-234.	3.8	7
299	Current perspective of venous thrombosis in the upper extremity: a rebuttal. Journal of Thrombosis and Haemostasis, 2009, 7, 237-238.	3.8	7
300	Antiphospholipid and antiâ€PF4 antibodies: an association affecting antiâ€PF4/heparin assay analysis. Journal of Thrombosis and Haemostasis, 2009, 7, 1067-1069.	3.8	7
301	The association between platelet activation and Fcl̂³Rlla proteolysis. Journal of Thrombosis and Haemostasis, 2011, 9, 885-887.	3.8	7
302	The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by "true―heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2012, 107, 998-1000.	3.4	7
303	4Ts scoring with hemofiltration or hemodialysis clotting. Journal of Clinical Monitoring and Computing, 2015, 29, 7-9.	1.6	7
304	Acute intraoperative HIT during heart surgery: Why so rare?. Thrombosis Research, 2016, 146, 110-112.	1.7	7
305	Symmetrical Peripheral Gangrene: Mechanisms for Limb Loss in the ICU in Patients With Retained Pulses. Clinical Pulmonary Medicine, 2018, 25, 61-66.	0.3	7
306	Maximum 24â€hour platelet count fall: Metric for improving the diagnosis of heparinâ€induced thrombocytopenia among patients with intermediate probability 4Ts scores. Journal of Thrombosis and Haemostasis, 2020, 18, 2018-2024.	3.8	7

#	Article	IF	CITATIONS
307	Thrombin generation, ProC(®)Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for seven days and after methylene blue/light pathogen inactivation. Blood Transfusion, 2016, 14, 66-72.	0.4	7
308	Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. Minerva Medica, 2022, 112, .	0.9	7
309	Vaccine-induced immune thrombotic thrombocytopenia (VITT). Seminars in Hematology, 2022, 59, 57-58.	3.4	7
310	Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. Blood Advances, 2022, 6, 4137-4146.	5.2	7
311	SARS-CoV-2 Infection in Patients with a History of VITT. New England Journal of Medicine, 2022, 387, 88-90.	27.0	7
312	Platelet Microparticle Generation Assay for Detection of HIT Antibodies: Advance, Retreat, or Too Soon to Tell?. Thrombosis Research, 2014, 133, 957-958.	1.7	6
313	Concurrence of symmetrical peripheral gangrene and venous limb gangrene following polytrauma: a case report. Journal of Medical Case Reports, 2018, 12, 131.	0.8	6
314	Anemia-Induced Bleeding in Patients with Platelet Disorders. Transfusion Medicine Reviews, 2021, 35, 22-28.	2.0	6
315	Pseudo-Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 261-282.	0.0	6
316	Treatment of Heparin-Induced ÂThrombocytopenia: An Overview. Fundamental and Clinical Cardiology, 2007, , 283-318.	0.0	6
317	The Epidemiology of Thrombosis With Thrombocytopenia Syndrome: Analogies With Heparin-Induced Thrombocytopenia. Annals of Internal Medicine, 2022, 175, 604-605.	3.9	6
318	Bacterial infectionâ€associated improvement of platelet counts in two patients with chronic and unresponsive idiopathic thrombocytopenic purpura with normal platelet survival studies. British Journal of Haematology, 1995, 90, 332-335.	2.5	5
319	PROTEOLYTIC DEGRADATION OF HIGH MOLECULAR WEIGHT KININOGEN IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA. British Journal of Haematology, 1997, 97, 762-767.	2.5	5
320	The paradox of heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2009, 7, 1472-1473.	3.8	5
321	DITP causation: 3 methods better than 1?. Blood, 2010, 116, 2002-2003.	1.4	5
322	A Novel Sickling Hemoglobinopathy. New England Journal of Medicine, 2011, 365, 1548-1549.	27.0	5
323	Hemodialysis-Associated Acute Systemic Reactions and Heparin-Induced Thrombocytopenia. Thrombosis Research, 2012, 129, 405-406.	1.7	5
324	Transient pseudothrombocytopenia associated with immune heparin-induced thrombocytopenia complicated by pulmonary embolism. Thrombosis and Haemostasis, 2013, 109, 971-973.	3.4	5

#	Article	IF	CITATIONS
325	Heparin-induced thrombocytopenia in 2017 and beyond. Thrombosis and Haemostasis, 2016, 116, 781-782.	3.4	5
326	Knee replacement and HIT without heparin. Blood, 2016, 127, 961-962.	1.4	5
327	Levofloxacin-Induced Acute Immune-Mediated Thrombocytopenia of Rapid-Onset. Journal of Pharmacy Practice, 2018, 31, 234-237.	1.0	5
328	Catastrophic antiphospholipid syndrome refractory to high-dose intravenous immunoglobulin responsive to therapeutic plasma exchange. Platelets, 2020, 32, 1-4.	2.3	5
329	HIT: still stringing us along. Blood, 2020, 135, 1193-1194.	1.4	5
330	Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: Fraternal—Not Identical—Twins. Thrombosis and Haemostasis, 2021, 121, 1558-1561.	3.4	5
331	Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia. Thrombosis Research, 2021, 206, 14-17.	1.7	5
332	Heparin and platelets. Hematology/Oncology Clinics of North America, 1990, 4, 243-64.	2.2	5
333	Immune mechanisms in heparinâ€induced thrombocytopenia: no evidence for immunoglobulin M antiâ€idiotype antibodies. Transfusion, 2009, 49, 1812-1818.	1.6	4
334	Voting with your fondaparinux. Thrombosis Research, 2014, 134, 3-4.	1.7	4
335	Thrombocytopenia Caused by Platelet Destruction, Hypersplenism, or Hemodilution. , 2018, , 1955-1972.		4
336	Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA-5b). Blood, 1992, 79, 2480-4.	1.4	4
337	Heparin-induced thrombocytopenia: yet another treatment paradox?. Thrombosis and Haemostasis, 2001, 85, 947-9.	3.4	4
338	Heparin-induced thrombocytopenia and the anesthesiologist. Canadian Journal of Anaesthesia, 2002, 49, S36-49.	1.6	4
339	Argatroban. Drugs, 2001, 61, 523-524.	10.9	3
340	Management of Immune Thrombocytopenia. , 0, , 344-375.		3
341	Old blood bad? Either the biggest issue in transfusion medicine or a nonevent. Transfusion, 2012, 52, 1165-1167.	1.6	3
342	Platelet Activation Testing for Heparin-Induced Thrombocytopenia Antibodies. Chest, 2016, 150, 478-480.	0.8	3

#	Article	IF	CITATIONS
343	Colloid Transfusion, Natural Anticoagulant Depletion, and Symmetric Peripheral Gangrene. New England Journal of Medicine, 2020, 383, 1592-1594.	27.0	3
344	Venous limb gangrene and pulseless electrical activity (PEA) cardiac arrest during management of deepâ€vein thrombosis and progressive limb ischemic necrosis following vascular surgery. American Journal of Hematology, 2020, 95, 712-717.	4.1	3
345	Multicentric warfarinâ€induced skin necrosis complicating heparinâ€induced thrombocytopenia. American Journal of Hematology, 1999, 62, 44-48.	4.1	3
346	Prothrombotic genetic risk factors and heparin-induced thrombocytopenia. Pharmacogenetics and Genomics, 2003, 13, 245-246.	5.7	2
347	Lepirudin: walking the dosing line. Blood, 2006, 108, 1428-1429.	1.4	2
348	Regression Analysis with a Misclassified Covariate from a Current Status Observation Scheme. Biometrics, 2010, 66, 415-425.	1.4	2
349	Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is â€~shock liver' the unrecognized provocateur of ischemic limb necrosis: reply. Journal of Thrombosis and Haemostasis, 2016, 14, 2317-2319.	3.8	2
350	B cells, PF4/heparin complexes, and complement. Blood, 2016, 128, 1781-1782.	1.4	2
351	Neutropenia and monocytopenia in recurrent anaphylactoid reactions after red blood cell transfusions in a woman with immunoglobulin A (IgA) deficiency and antiâ€lgA. Transfusion, 2018, 58, 2320-2325.	1.6	2
352	Inter-Rater Reliability of the 4Ts Scoring System for Diagnosing Heparin-Induced Thrombocytopenia in Critically Ill Patients Blood, 2009, 114, 3995-3995.	1.4	2
353	History of Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 1-20.	0.0	2
354	Letter of response to Peters and Vlaar commentary. Transfusion, 2016, 56, 2395-2397.	1.6	1
355	Sepsis and persisting neutropenia in a drug addict. American Journal of Hematology, 2017, 92, 312-316.	4.1	1
356	Limitations of the particle immunofiltration assay test for diagnosis of heparinâ€induced thrombocytopenia. American Journal of Hematology, 2020, 95, E250-E254.	4.1	1
357	RE: The prothrombin time ratio is not a more effective marker for evaluating sepsisâ€induced coagulopathy than fibrinâ€related markers: Response to the Letterâ€toâ€theâ€Editor by Dr Wada. Journal of Thrombosis and Haemostasis, 2020, 18, 1507-1509.	3.8	1
358	Post-cardiac surgery thrombotic thrombocytopenic purpura: presence of anti-ADAMTS13 autoantibodies at preoperative baseline. Platelets, 2021, , 1-5.	2.3	1
359	Heparin induced thrombocytopenia in relation to SARS-CoV-2 infection and ABO blood group. Thrombosis Research, 2021, 207, 62-65.	1.7	1
360	Spontaneous Heparin-Induced Thrombocytopenia Syndrome: Two New Cases and a Proposal For Defining This Disorder. Blood, 2013, 122, 2328-2328.	1.4	1

#	Article	lF	CITATIONS
361	Combination Of 4T's Score and Rapid Gel Centrifugation Assay Excludes HIT In a Prospective Cohort Study. Blood, 2013, 122, 3535-3535.	1.4	1
362	Editorial on Thaler et al. long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thromb Res 2021 in press. Thrombosis Research, 2021, 207, 158-160.	1.7	1
363	Towards a Conceptual Framework for Diagnosis of Heparin-Induced Thrombocytopenia (HIT) Blood, 2005, 106, 1234-1234.	1.4	1
364	Acute thrombocytopenia suggesting thrombotic microangiopathy. American Journal of Hematology, 2022, 97, 659-665.	4.1	1
365	How to dose and monitor argatroban for treatment of <scp>HIT</scp> . British Journal of Haematology, 2022, 197, 653-655.	2.5	1
366	Impact of laboratory testing for heparin-induced antibodies: using Bayes' rule to prevent overdiagnosis of heparin-induced thrombocytopenia/Bedeutung von Laboruntersuchungen von Heparin-induzierten Antik¶rpern: Einsatz des Bayes Wahrscheinlichkeitstheorems zur Pr¤ention der Überdiagnose einer Heparin-induzierten Thrombozytopenie. Laboratoriums Medizin, 2011, 35, 45-54.	0.6	0
367	An Instrument-based Immunoassay with an Appropriate Normal Range: Minimizing HIT Overdiagnosis. Thrombosis Research, 2014, 133, 961-962.	1.7	Ο
368	Safe bridging to warfarin in heparin-induced thrombocytopenia. Thrombosis Research, 2016, 144, 226-228.	1.7	0
369	Management of immune-mediated thrombocytopenia. , 2016, , 245-264.		0
370	Natural, not immune; classical, not alternative. Blood, 2018, 132, 2421-2422.	1.4	0
371	Acquired Thrombocytopenia. , 2019, , 135-148.		0
372	Pitfalls in Diagnosing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Critical Care Medicine, 2021, Publish Ahead of Print, .	0.9	0
373	Argatroban Inhibits Human Factor Xa at Therapeutic Drug Levels: An Explanation for Its Prolongation of the INR Blood, 2004, 104, 1845-1845.	1.4	0
374	An Algorithm for "Indeterminate―Test Results in the Platelet Serotonin Release Assay for Heparin-Induced Thrombocytopenia (HIT) Blood, 2006, 108, 1048-1048.	1.4	0
375	Incidence of HPA-9b in Testing for Neonatal Alloimmune Thrombocytopenia Blood, 2007, 110, 3214-3214.	1.4	0
376	Identifying Drugs Implicated in Drug-Induced Immune Thrombocytopenia Using Levels of Evidence Applied to Laboratory Tests,. Blood, 2011, 118, 3304-3304.	1.4	0
377	If the Platelets Are Low, Is It HIT?. Difficult Decisions in Surgery: an Evidence-based Approach, 2019, , 455-479.	0.0	0
378	Diagnosis and Management of Heparin-Induced Thrombocytopenia. , 0, , 158-167.		0